Abstracts tagged "COVID-19"

Abstract Number: 1280 • ACR Convergence 2025
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Yonatan Butbul Aviel¹, Arad Dotan², Dana Arnheim² and Cynthia Freiberg³, ¹Rambam Health Care Campus, Haifa, Israel, ²Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, Tel Aviv, Israel, ³Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv
Background/Purpose: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Madison Negron¹, Jiaqi Wang², Xiaosong Wang³, Lauren O'Keeffe⁴, Grace Qian⁴, Kevin Mueller⁴, Alene Saavedra⁴, Natalie Davis⁵, Liya Sisay Getachew⁶, Jeffrey Sparks⁶ and Naomi Patel⁷, ¹Harvard Extension School, Medford, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
Abstract Number: 1068 • ACR Convergence 2025
Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
Londyn Robinson¹, jerrod anzalone², Jasvinder Singh³, Kaleb Michaud², Lesley Jackson⁴, Maria I. ("Maio") Danila⁵, Dongmei Li⁶, Rena Patel⁴ and Namrata Singh⁷, ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³Baylor College of Medicine, Houston, TX, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁶University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁷University of Washington, Bellevue, WA
Background/Purpose: Although studies have been published on the baseline characteristics of patients with autoimmune rheumatic diseases (AIRDs) with COVID-19 infection, little data exists on how…
Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Liya Sisay Getachew¹, Xiaosong Wang², Zachary Wallace³, Naomi Patel⁴, Lauren O'Keeffe⁵, Madison Negron⁶, Grace Qian⁵, Alene Saavedra⁵, Kevin Mueller⁵, Natalie Davis⁷, Yijia Li⁸, Manish Choudhary⁵, Julie Boucau³, Brooke Leeman⁵, Gregory Edelstein⁵, Owen Glover³, Yumeko Kawano⁵, Rinki Deo⁵, Caitlin Marino³, Zahra Reynolds³, Karry Su³, Chase Mandell³, Eliza Passell³, Mamadou Barry³, Andrew Alexandrescu³, Dibya Ghimire³, Mriganka Mandal⁹, Tammy Vyas³, Sarah Hammond³, Jatin Vyas³, Jacob Lemieux³, Mark Siedner³, Amy Barczak³, Jonathan Li³ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Harvard Extension School, Medford, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸University of Pittsburgh, Pittsburgh, ⁹Dana-Farber Cancer Institute, Boston
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 0172 • ACR Convergence 2024
Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies
Brandon Levian¹, Charlotte Botz², Jason Chwa², Sophie Grove², Vignesh Ravi², Branden Ireifej³, daniel arkfeld⁴, Diana Hanna², Jenny Hu² and Binh Ngo², ¹Keck School of Medicine, Beverly Hills, CA, ²Keck School of Medicine, Los Angeles, ³LAGMC/Keck School of Medicine, Los Angeles, CA, ⁴Keck Medical Center of USC, RANCHO PALOS VERDES, CA
Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
Abstract Number: 1921 • ACR Convergence 2024
Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
Kari Falaas¹, Michael Schnaus², Margaret Singer³, Allison Hochstetler³, Pang Nhia Khang⁴, Katherine Schmiechen⁴ and Elie Gertner³, ¹University of Minnesota, Regions Hospital, Minneapolis, MN, ²University of Minnesota, Regions Hospital, Methodist Hospital, Minneapolis, ³University of Minnesota, Regions Hospital, Minneapolis, ⁴Regions Hospital, Minneapolis
Background/Purpose: Hyperuricemia is associated with an elevated risk of developing cardiovascular diseases, diabetes, chronic kidney disease, and metabolic syndromes. The Hmong population, in particular, has…
Abstract Number: 0173 • ACR Convergence 2024
Systemic Lupus Erythematosus Mortality—United States, 2018–2022
Danielle Dawson¹, Kurt Greenlund² and Kamil Barbour², ¹CDC, Atlanta, GA, ²CDC, Alpharetta, GA
Background/Purpose: Mortality due to cardiovascular disease, infections, and renal disease is elevated in people with systemic lupus erythematosus (SLE) compared with the general population, but…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1982 • ACR Convergence 2024
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Sarah Ifteqar¹, Mallak Zatreh², Aatif Syed¹, Xiangni Wu³, Asad Kabir⁴, John Foxworth⁵ and AMR EDREES⁶, ¹University of Missouri Kansas City, Kansas City, MO, ²3. Hutchinson Regional Medical Center, Hutchinson, Kansas, USA, Kansas City, ³UMKC, KANSAS CITY, MO, ⁴5. Pulmonary Critical Care, Mosaic Life Care Health System, St. Joseph, Missouri, USA, Kansas City, ⁵2. Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA, Kansas City, ⁶UMKC, Overland Park, KS
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus affect 3-5% of Americans and causes significant morbidity due to chronic…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].